"Legislation that would have authorized “nurse practitioners” to treat patients without the supervision of a physician, including prescribing drugs, was rejected Tuesday by the Assembly Business and Professions Committee.
The lopsided, 8-4 vote against the measure, Senate Bill 323, was a climax to this year’s version of the Capitol’s perennial war among medical factions over “scope of practice.”"
Read more at Sacramento Bee
"More than half of U.S. residents want to access health information via their doctors' websites, but few currently do so, according to a survey published Wednesday in the Journal of General Internal Medicine. The researchers found that about 57% of survey respondents said they wanted to be able to use their physicians' sites to access medical information, but only 7% reported currently doing so."
Read more on California Healthline and Tech Times
"The United States says Novartis AG (NOVN.VX) should pay as much as $3.35 billion in damages and civil fines because the Swiss drugmaker used kickbacks to boost sales of two drugs covered by Medicare and Medicaid.
In papers filed Monday night in Manhattan federal court, the government said it deserves that sum under the federal False Claims Act over alleged improper reimbursements for Exjade, used by patients who receive blood transfusions, and Myfortic, for patients with kidney transplants.
The government is seeking up to $1.52 billion in damages, representing triple the sums allegedly reimbursed and tainted by kickbacks between 2004 and 2013."
Read more at Reuters
" U.S. doctors and teaching hospitals got $6.49 billion from drug and medical-device makers in 2014, according to new government data on the financial links between the companies and the people who prescribe their products.
The data released Tuesday range from the royalties paid to hospitals to help develop products to fees provided to medical experts to speak at a dinner with colleagues. The payments are listed in two broad categories: money to fund research and payments to entertain doctors or compensate them for consulting or other non-research purposes."
Read more at Bloomberg